{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:23Z","timestamp":1788546683262,"version":"build-2803163510"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Maternal and Child Research Institute (MCHRI), Lurie's Children's Hospital\/Northwestern University, and American Society of Hematology Hematology Inclusion Pathway Fellowship"},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-03006-0","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:55:28Z","timestamp":1782395728000},"page":"1587-1599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunological mechanisms and therapeutic advances in chronic myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-4984","authenticated-orcid":false,"given":"Tiffany K.","family":"Ybarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Sathianathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2308-4425","authenticated-orcid":false,"given":"Rohaum","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-054X","authenticated-orcid":false,"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3388","authenticated-orcid":false,"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-8838","authenticated-orcid":false,"given":"Kathleen M.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"3006_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"3006_CR2","unstructured":"Phases of Chronic Myeloid Leukemia: American Cancer Society. Available from: https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/detection-diagnosis-staging\/staging.html."},{"key":"3006_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3006_CR4","unstructured":"SEER Cancer Stat Facts: Chronic Myeloid Leukemia. National Cancer Institute. Bethesda, MD, [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"3006_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3332\/ecancer.2020.1089","volume":"14","author":"O Henke","year":"2020","unstructured":"Henke O, Mapendo PJ, Mkwizu EW, le Coutre P. Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment. Ecancermedicalscience. 2020;14:1089.","journal-title":"Ecancermedicalscience"},{"key":"3006_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","volume":"9","author":"L Ning","year":"2020","unstructured":"Ning L, Hu C, Lu P, Que Y, Zhu X, Li D. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020;9:29.","journal-title":"Exp Hematol Oncol"},{"key":"3006_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","volume":"62","author":"N Hijiya","year":"2015","unstructured":"Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am. 2015;62:107\u201319.","journal-title":"Pediatr Clin North Am"},{"key":"3006_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392\u20139.","journal-title":"Blood"},{"key":"3006_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/2168479015570335","volume":"49","author":"K Hanada","year":"2015","unstructured":"Hanada K, Kaneko M, Narukawa M. Comparison of approved dosages for pediatric and adult populations based on US labeling information. Ther Innov Regul Sci. 2015;49:576\u201383.","journal-title":"Ther Innov Regul Sci"},{"key":"3006_CR10","doi-asserted-by":"crossref","unstructured":"Youn M, Smith SM, Lee AG, Chae HD, Spiteri E, Erdmann J, et al. Comparison of the transcriptomic signatures in pediatric and adult CML. Cancers. 2021;13:1-8.","DOI":"10.3390\/cancers13246263"},{"key":"3006_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bjh.70134","volume":"207","author":"M Metzler","year":"2025","unstructured":"Metzler M, Branford S, Hijiya N, Sakamoto K. An old leukaemia in young patients\u2014genetic characteristics of paediatric chronic myeloid leukaemia. Br J Haematol. 2025;207:1782\u20138.","journal-title":"Br J Haematol"},{"key":"3006_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/gcc.21989","volume":"51","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer. 2012;51:1045\u201353.","journal-title":"Genes Chromosomes Cancer"},{"key":"3006_CR13","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"3006_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342.","journal-title":"N Engl J Med"},{"key":"3006_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023\u2014 common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J"},{"key":"3006_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11899-022-00673-5","volume":"17","author":"M Ford","year":"2022","unstructured":"Ford M, Mauro M, Aftandilian C, Sakamoto KM, Hijiya N. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022;17:121\u20136.","journal-title":"Curr Hematol Malig Rep"},{"key":"3006_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"El-Tanani","year":"2024","unstructured":"El-Tanani, Nsairat M, Matalka II H, Lee YF, Rizzo M, Aljabali AA, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254:155161.","journal-title":"Pathol Res Pract"},{"key":"3006_CR18","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"3006_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Saussele S, Dietz CT, M\u00fcller MC, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829\u201336.","journal-title":"Leukemia"},{"key":"3006_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"3006_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","volume":"38","author":"J Huuhtanen","year":"2024","unstructured":"Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forst\u00e9n S, Warfvinge R, Dufva O, et al. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 2024;38:109\u201325.","journal-title":"Leukemia"},{"key":"3006_CR22","doi-asserted-by":"crossref","unstructured":"Kwa\u015bnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysogl\u0105d H, Ochrem B, et al. High level of CD8(+)PD-1(+) cells in patients with chronic myeloid leukemia who experienced loss of MMR after imatinib discontinuation. Cells. 2024;13:1\u201315.","DOI":"10.3390\/cells13080723"},{"key":"3006_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"3006_CR24","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.18632\/oncotarget.22279","volume":"8","author":"M Ilander","year":"2017","unstructured":"Ilander M, Mustjoki S. Immune control in chronic myeloid leukemia. Oncotarget. 2017;8:102763\u20134.","journal-title":"Oncotarget"},{"key":"3006_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fimmu.2016.00184","volume":"7","author":"A Bonomo","year":"2016","unstructured":"Bonomo A, Monteiro AC, Gon\u00e7alves-Silva T, Cordeiro-Spinetti E, Galvani RG, Balduino A. A T cell view of the bone marrow. Front Immunol. 2016;7:184.","journal-title":"Front Immunol"},{"key":"3006_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00018-024-05445-3","volume":"81","author":"H Xu","year":"2024","unstructured":"Xu H, Li Y, Gao Y. The role of immune cells settled in the bone marrow on adult hematopoietic stem cells. Cell Mol Life Sci. 2024;81:420.","journal-title":"Cell Mol Life Sci"},{"key":"3006_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood-2004-07-2856","volume":"105","author":"Monteiro JoP","year":"2005","unstructured":"JoP Monteiro, Benjamin A, Costa ES, Barcinski MA, Bonomo A. Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood. 2005;105:1484\u201391.","journal-title":"Blood"},{"key":"3006_CR28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1126\/science.1196509","volume":"330","author":"JE Mold","year":"2010","unstructured":"Mold JE, Venkatasubrahmanyam S, Burt TD, Micha\u00eblsson J, Rivera JM, Galkina SA, et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science. 2010;330:1695\u20139.","journal-title":"Science"},{"key":"3006_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.stem.2022.04.007","volume":"29","author":"P Hern\u00e1ndez-Malmierca","year":"2022","unstructured":"Hern\u00e1ndez-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022;29:760\u201375.e10.","journal-title":"Cell Stem Cell"},{"key":"3006_CR30","first-page":"2023","volume":"ume 14","author":"D Yao","year":"2023","unstructured":"Yao D, Lai J, Lu Y, Zhong J, Zha X, Huang X, et al. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. Front Immunol. 2023;ume 14:2023.","journal-title":"Front Immunol"},{"key":"3006_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4252\/wjsc.v11.i8.476","volume":"11","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Blanco TM, Circosta P, Yazdi N, Kazemi A, Saglio G, et al. Bone marrow microenvironment: The guardian of leukemia stem cells. World J Stem Cells. 2019;11:476\u201390.","journal-title":"World J Stem Cells"},{"key":"3006_CR32","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32:1643\u201356.","journal-title":"Leukemia"},{"key":"3006_CR33","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.exphem.2006.07.009","volume":"34","author":"M Schmitt","year":"2006","unstructured":"Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T, et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol. 2006;34:1709\u201319.","journal-title":"Exp Hematol"},{"key":"3006_CR34","doi-asserted-by":"publisher","first-page":"8210","DOI":"10.4049\/jimmunol.174.12.8210","volume":"174","author":"M Gannag\u00e9","year":"2005","unstructured":"Gannag\u00e9 M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174:8210\u20138.","journal-title":"J Immunol"},{"key":"3006_CR35","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018\u201323.","journal-title":"Nat Med"},{"key":"3006_CR36","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166\u201376.","journal-title":"Blood"},{"key":"3006_CR37","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"H Kolb","year":"1995","unstructured":"Kolb H, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood. 1995;86:2041\u201350.","journal-title":"Blood"},{"key":"3006_CR38","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.it.2008.09.004","volume":"29","author":"X Feng","year":"2008","unstructured":"Feng X, Hui KM, Younes HM, Brickner AG. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol. 2008;29:624\u201332.","journal-title":"Trends Immunol"},{"key":"3006_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1172\/JCI10196","volume":"106","author":"CJ Wu","year":"2000","unstructured":"Wu CJ, Yang X-F, McLaughlin S, Neuberg D, Canning C, Stein B, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Investig. 2000;106:705\u201314.","journal-title":"J Clin Investig"},{"key":"3006_CR40","first-page":"817","volume":"111","author":"X Chen","year":"2000","unstructured":"Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000;111:817\u201325.","journal-title":"Br J Haematol"},{"key":"3006_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/102453309X385241","volume":"14","author":"S Chen","year":"2009","unstructured":"Chen S, Yang L, Chen S, Li YTCR. zeta chain expression in T cells from patients with CML. Hematology. 2009;14:95\u2013100.","journal-title":"Hematology"},{"key":"3006_CR42","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI-U Chen","year":"2008","unstructured":"Chen CI-U, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood. 2008;111:5342\u20139.","journal-title":"Blood"},{"key":"3006_CR43","first-page":"762","volume":"88","author":"JL Steegmann","year":"2003","unstructured":"Steegmann JL, Moreno G, Al\u00e1ez C, Osorio S, Granda A, de la C\u00e1mara R, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica. 2003;88:762\u20138.","journal-title":"Haematologica"},{"key":"3006_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood-2024-204864","volume":"144","author":"SD Patterson","year":"2024","unstructured":"Patterson SD, Nosratzadeh I, Young R, Hair A, Cassels J, Clark RE, et al. Common lymphoid progenitors and B cell subpopulations in the bone marrow are predictive of treatment-free remission in chronic myeloid leukemia. Blood. 2024;144:994.","journal-title":"Blood"},{"key":"3006_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H de Lavallade","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"3006_CR46","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/blood-2011-01-327932","volume":"119","author":"T Kawamata","year":"2012","unstructured":"Kawamata T, Lu J, Sato T, Tanaka M, Nagaoka H, Agata Y, et al. Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood. 2012;119:3123\u20137.","journal-title":"Blood"},{"key":"3006_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155120","volume":"254","author":"MJ Saadh","year":"2024","unstructured":"Saadh MJ, Rasulova I, Khalil M, Farahim F, S\u00e2rbu I, Ciongradi CI, et al. Natural killer cell-mediated immune surveillance in cancer: role of tumor microenvironment. Pathol - Res Pr. 2024;254:155120.","journal-title":"Pathol - Res Pr"},{"key":"3006_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1159\/000525935","volume":"145","author":"J Dengler","year":"2022","unstructured":"Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, et al. Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German hematology practices. Acta Haematol. 2022;145:603\u201310.","journal-title":"Acta Haematol"},{"key":"3006_CR49","first-page":"2019","volume":"ume 10","author":"M Carlsten","year":"2019","unstructured":"Carlsten M, J\u00e4r\u00e5s M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019;ume 10:2019.","journal-title":"Front Immunol"},{"key":"3006_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/jcm10010042","volume":"10","author":"L Vig\u00f3n","year":"2021","unstructured":"Vig\u00f3n L, Luna A, Gal\u00e1n M, Rodr\u00edguez-Mora S, Fuertes D, Mateos E, et al. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission. J Clin Med. 2021;10:42.","journal-title":"J Clin Med"},{"key":"3006_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/ijh.ijh_77_23","volume":"12","author":"YF Faraj","year":"2023","unstructured":"Faraj YF, Salih KM, Khelif A, Hameed EZ. Subsets of natural killer cells in chronic myeloid leukemia and their relation with some inflammatory cytokines. Iraqi J Hematol. 2023;12:184\u20139.","journal-title":"Iraqi J Hematol"},{"key":"3006_CR52","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"R Delphine","year":"2017","unstructured":"Delphine R, Guylaine H, Zena K, Gabriel E, Fran\u00e7ois G, Franck N, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"3006_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1241600","volume":"14","author":"MB S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez MB, Vasconcelos C\u00f3rdoba B, Pavlovsky C, Moiraghi B, Varela A, Custidiano R, et al. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy. Front Immunol. 2023;14:1241600.","journal-title":"Front Immunol"},{"key":"3006_CR54","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T, Gr\u00fcnebach F, Steinle A, Salih HR, et al. The BCR\/ABL inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127:2119\u201328.","journal-title":"Int J Cancer"},{"key":"3006_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hon.2034","volume":"31","author":"T Uchiyama","year":"2013","unstructured":"Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, et al. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in an in vitro study. Hematol Oncol. 2013;31:156\u201363.","journal-title":"Hematol Oncol"},{"key":"3006_CR56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/cancers12040774","volume":"12","author":"L Damele","year":"2020","unstructured":"Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Targeted therapies: friends or foes for patients\u2019 NK cell-mediated tumor immune-surveillance? Cancers. 2020;12:774.","journal-title":"Cancers"},{"key":"3006_CR57","first-page":"2023","volume":"ume 14","author":"C Jim\u00e9nez-Cortegana","year":"2024","unstructured":"Jim\u00e9nez-Cortegana C, Palomares F, Alba G, Santa-Mar\u00eda C, de la Cruz-Merino L, S\u00e1nchez-Margalet V, et al. Dendritic cells: the yin and yang in disease progression. Front Immunol. 2024;ume 14:2023.","journal-title":"Front Immunol"},{"key":"3006_CR58","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/10428190400029825","volume":"46","author":"K Eisendle","year":"2005","unstructured":"Eisendle K, Wolf D, Gastl G, Kircher-Eibl B. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. Leuk Lymphoma. 2005;46:663\u201370.","journal-title":"Leuk Lymphoma"},{"key":"3006_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2141.2002.03831.x","volume":"119","author":"M Mohty","year":"2002","unstructured":"Mohty M, Isnardon D, Vey N, Bri\u00e8re F, Blaise D, Olive D, et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+\/CD38- primitive haematopoietic progenitors. Br J Haematol. 2002;119:115\u20138.","journal-title":"Br J Haematol"},{"key":"3006_CR60","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-18-1477","volume":"78","author":"S Inselmann","year":"2018","unstructured":"Inselmann S, Wang Y, Saussele S, Fritz L, Sch\u00fctz C, Huber M, et al. Development, function, and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res. 2018;78:6223\u201334.","journal-title":"Cancer Res"},{"key":"3006_CR61","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23:692\u2013702.","journal-title":"Nat Med"},{"key":"3006_CR62","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/blood-2018-99-112119","volume":"132","author":"A Hochhaus","year":"2018","unstructured":"Hochhaus A, Saussele S, Baerlocher GM, Br\u00fcmmendorf TH, Burchert A, La Ros\u00e9e P, et al. Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. Blood. 2018;132:460.","journal-title":"Blood"},{"key":"3006_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2021-148369","volume":"138","author":"F-X Mahon","year":"2021","unstructured":"Mahon F-X, Richter J, Hochhaus A, Panayiotidis P, Medina de Almeida A, Mayer J, et al. FINAL analysis of a PAN European STOP tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Blood. 2021;138:633.","journal-title":"Blood"},{"key":"3006_CR64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138:105\u201315.","journal-title":"Immunology"},{"key":"3006_CR65","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107","volume":"5","author":"C Giallongo","year":"2015","unstructured":"Giallongo C, Parrinello N, Brundo MV, Raccuia SA, Di Rosa M, La Cava P, et al. Myeloid-derived suppressor cells in chronic myeloid leukemia. Front Oncol. 2015;5:107.","journal-title":"Front Oncol"},{"key":"3006_CR66","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3109\/08820139.2012.678023","volume":"41","author":"S Solito","year":"2012","unstructured":"Solito S, Pinton L, Damuzzo V, Mandruzzato S. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol Invest. 2012;41:722\u201337.","journal-title":"Immunol Invest"},{"key":"3006_CR67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/cmi.2013.2","volume":"10","author":"I Pedroza-Pacheco","year":"2013","unstructured":"Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol. 2013;10:222\u20139.","journal-title":"Cell Mol Immunol"},{"key":"3006_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","volume":"153","author":"E Bachy","year":"2011","unstructured":"Bachy E, Bernaud J, Roy P, Rigal D, Nicolini FE. Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol. 2011;153:139\u201343.","journal-title":"Br J Haematol"},{"key":"3006_CR69","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10147-013-0615-9","volume":"19","author":"AM Zahran","year":"2014","unstructured":"Zahran AM, Badrawy H, Ibrahim A. Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int J Clin Oncol. 2014;19:753\u201360.","journal-title":"Int J Clin Oncol"},{"key":"3006_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61.","journal-title":"J Hematol Oncol"},{"key":"3006_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.714","volume":"5","author":"R Wang","year":"2024","unstructured":"Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M, et al. The interaction of innate immune and adaptive immune system. MedComm. 2024;5:e714.","journal-title":"MedComm"},{"key":"3006_CR72","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"3006_CR73","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"Y-C Hsieh","year":"2021","unstructured":"Hsieh Y-C, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021;35:1229\u201342.","journal-title":"Leukemia"},{"key":"3006_CR74","first-page":"2017","volume":"ume 8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;ume 8:2017.","journal-title":"Front Immunol"},{"key":"3006_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"3006_CR76","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114:1528\u201336.","journal-title":"Blood"},{"key":"3006_CR77","first-page":"2024","volume":"ume 15","author":"A Decroos","year":"2024","unstructured":"Decroos A, Meddour S, Demoy M, Piccirilli N, Rousselot P, Nicolini FE, et al. The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy. Front Immunol. 2024;ume 15:2024.","journal-title":"Front Immunol"},{"key":"3006_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/gene.2009.83","volume":"11","author":"L Handunnetthi","year":"2010","unstructured":"Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC. Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. Genes Immun. 2010;11:99\u2013112.","journal-title":"Genes Immun"},{"key":"3006_CR79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2016-11-750554","volume":"129","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE. CML stem cells: evasion for better invasion. Blood. 2017;129:141\u20132.","journal-title":"Blood"},{"key":"3006_CR80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","volume":"129","author":"A Tarafdar","year":"2017","unstructured":"Tarafdar A, Hopcroft LEM, Gallipoli P, Pellicano F, Cassels J, Hair A, et al. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 2017;129:199\u2013208.","journal-title":"Blood"},{"key":"3006_CR81","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9:2064\u201378.","journal-title":"Am J Cancer Res"},{"key":"3006_CR82","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1158\/0008-5472.CAN-04-2675","volume":"65","author":"M Terme","year":"2005","unstructured":"Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, et al. BCR\/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res. 2005;65:6409\u201317.","journal-title":"Cancer Res"},{"key":"3006_CR83","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.4049\/jimmunol.176.8.5108","volume":"176","author":"N Boissel","year":"2006","unstructured":"Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, et al. BCR\/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol. 2006;176:5108\u201316.","journal-title":"J Immunol"},{"key":"3006_CR84","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","volume":"83","author":"T Shammas","year":"2025","unstructured":"Shammas T, Peiris MN, Meyer AN, Donoghue DJ. BCR-ABL: The molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev. 2025;83:45\u201358.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3006_CR85","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14:1\u201322.","DOI":"10.3390\/pharmaceutics14010215"},{"key":"3006_CR86","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","volume":"12","author":"H Mojtahedi","year":"2021","unstructured":"Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther. 2021;12:603.","journal-title":"Stem Cell Res Ther"},{"key":"3006_CR87","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.3390\/cancers13225822","volume":"13","author":"K Ito","year":"2021","unstructured":"Ito K, Ito K. Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia. Cancers. 2021;13:5822.","journal-title":"Cancers"},{"key":"3006_CR88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11899-023-00688-6","volume":"18","author":"SD Patterson","year":"2023","unstructured":"Patterson SD, Copland M. The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities. Curr Hematol Malignancy Rep. 2023;18:19\u201332.","journal-title":"Curr Hematol Malignancy Rep"},{"key":"3006_CR89","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","volume":"9","author":"F Loscocco","year":"2019","unstructured":"Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939.","journal-title":"Front Oncol"},{"key":"3006_CR90","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","volume":"159","author":"SK Chai","year":"1997","unstructured":"Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720\u20138.","journal-title":"J Immunol"},{"key":"3006_CR91","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1126\/science.7569929","volume":"269","author":"NN Danial","year":"1995","unstructured":"Danial NN, Pernis A, Rothman PB. Jak-STAT signaling Induced by the v-abl oncogene. Science. 1995;269:1875\u20137.","journal-title":"Science"},{"key":"3006_CR92","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001;20:6188\u201395.","journal-title":"Oncogene"},{"key":"3006_CR93","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","volume":"18","author":"S Dumon","year":"1999","unstructured":"Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, Boucheron C, et al. IL-3-dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow-derived cell line. Oncogene. 1999;18:4191\u20139.","journal-title":"Oncogene"},{"key":"3006_CR94","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5\u2013dependent expression of Bcl-XL. J Exp Med. 2000;191:977\u201384.","journal-title":"J Exp Med"},{"key":"3006_CR95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1084\/jem.20042541","volume":"202","author":"Y Kato","year":"2005","unstructured":"Kato Y, Iwama A, Tadokoro Y, Shimoda K, Minoguchi M, Akira S, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med. 2005;202:169\u201379.","journal-title":"J Exp Med"},{"key":"3006_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","volume":"7","author":"R Moriggl","year":"2005","unstructured":"Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7:87\u201399.","journal-title":"Cancer Cell"},{"key":"3006_CR97","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41375-018-0369-5","volume":"33","author":"S Kollmann","year":"2019","unstructured":"Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, et al. Twins with different personalities: STAT5B\u2014but not STAT5A\u2014has a key role in BCR\/ABL-induced leukemia. Leukemia. 2019;33:1583\u201397.","journal-title":"Leukemia"},{"key":"3006_CR98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature. 2015;525:380\u20133.","journal-title":"Nature"},{"key":"3006_CR99","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1947601910397187","volume":"1","author":"SS Jatiani","year":"2010","unstructured":"Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010;1:979\u201393.","journal-title":"Genes Cancer"},{"key":"3006_CR100","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","volume":"96","author":"X Jiang","year":"1999","unstructured":"Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 1999;96:12804\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3006_CR101","unstructured":"SWOG Cancer Research Network. Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia. ClinicalTrials.gov NCT03654768. Updated May 20, 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03654768."},{"key":"3006_CR102","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature01593","volume":"423","author":"T Reya","year":"2003","unstructured":"Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409\u201314.","journal-title":"Nature"},{"key":"3006_CR103","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","volume":"26","author":"AM Coluccia","year":"2007","unstructured":"Coluccia AM, Vacca A, Du\u00f1ach M, Mologni L, Redaelli S, Bustos VH, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. Embo J. 2007;26:1456\u201366.","journal-title":"Embo J"},{"key":"3006_CR104","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3006_CR105","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","volume":"115","author":"SK McWeeney","year":"2010","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010;115:315\u201325.","journal-title":"Blood"},{"key":"3006_CR106","doi-asserted-by":"publisher","first-page":"54-","DOI":"10.1182\/blood.V126.23.54.54","volume":"126","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Zhang B, Ho Y, Cook A, Li L, Wang Y, et al. Inhibition of CML stem cell renewal by the porcupine inhibitor WNT974. Blood. 2015;126:54-.","journal-title":"Blood"},{"key":"3006_CR107","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","volume":"129","author":"P Agarwal","year":"2017","unstructured":"Agarwal P, Zhang B, Ho Y, Cook A, Li L, Mikhail FM, et al. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood. 2017;129:1008\u201320.","journal-title":"Blood"},{"key":"3006_CR108","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fonc.2019.00532","volume":"9","author":"S Grassi","year":"2019","unstructured":"Grassi S, Palumbo S, Mariotti V, Liberati D, Guerrini F, Ciabatti E, et al. The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia. Front Oncol. 2019;9:532.","journal-title":"Front Oncol"},{"key":"3006_CR109","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528\u201341.","journal-title":"Cancer Cell"},{"key":"3006_CR110","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI35660","volume":"119","author":"C Bellodi","year":"2009","unstructured":"Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor\u2013induced cell death in Philadelphia chromosome\u2013positive cells, including primary CML stem cells. J Clin Investig. 2009;119:1109\u201323.","journal-title":"J Clin Investig"},{"key":"3006_CR111","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3109\/10428194.2010.546913","volume":"52","author":"B Calabretta","year":"2011","unstructured":"Calabretta B, Salomoni P. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:54\u20139.","journal-title":"Leuk Lymphoma"},{"key":"3006_CR112","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/15680096113139990088","volume":"13","author":"GV Helgason","year":"2013","unstructured":"Helgason GV, Mukhopadhyay A, Karvela M, Salomoni P, Calabretta B, Holyoake TL. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets. 2013;13:724\u201334.","journal-title":"Curr Cancer Drug Targets"},{"key":"3006_CR113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","volume":"25","author":"C Talati","year":"2018","unstructured":"Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Curr Opin Hematol. 2018;25:154\u201361.","journal-title":"Curr Opin Hematol"},{"key":"3006_CR114","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","volume":"9","author":"M Bonifacio","year":"2019","unstructured":"Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in the advanced phase. Front Oncol. 2019;9:1132.","journal-title":"Front Oncol"},{"key":"3006_CR115","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"},{"key":"3006_CR116","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"3006_CR117","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"3006_CR118","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/leu.2017.264","volume":"31","author":"W Qiang","year":"2017","unstructured":"Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31:2844\u20137.","journal-title":"Leukemia"},{"key":"3006_CR119","doi-asserted-by":"crossref","unstructured":"Batar P, Mezei G, Illes A. Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1\/A337V can be effectively overcome with dasatinib treatment. Curr Oncol. 2025;32:1\u20135.","DOI":"10.3390\/curroncol32020097"},{"key":"3006_CR120","first-page":"764","volume":"111","author":"BK Jung","year":"2026","unstructured":"Jung BK, Weissmann S, Schock C, Meggendorfer M, Haferlach T, Dicker F. Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study. Haematologica. 2026;111:764\u20137.","journal-title":"Haematologica"},{"key":"3006_CR121","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/bmt.2011.194","volume":"47","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transpl. 2012;47:810\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"3006_CR122","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","volume":"69","author":"M Talpaz","year":"1987","unstructured":"Talpaz M, Kantarjian H, McCredie K, Keating M, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987;69:1280\u20138.","journal-title":"Blood"},{"key":"3006_CR123","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","volume":"66","author":"H Kantarjian","year":"1985","unstructured":"Kantarjian H, Smith T, McCredie K, Keating M, Walters R, Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66:1326\u201335.","journal-title":"Blood"},{"key":"3006_CR124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00277-015-2326-y","volume":"94","author":"M Talpaz","year":"2015","unstructured":"Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94:195\u2013207.","journal-title":"Ann Hematol"},{"key":"3006_CR125","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jir.2012.0120","volume":"33","author":"BL Stein","year":"2013","unstructured":"Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013;33:145\u201353.","journal-title":"J Interferon Cytokine Res"},{"key":"3006_CR126","doi-asserted-by":"crossref","unstructured":"Selleri C, Sato T, Vecchio LD, Luciano L, Barrett AJ, Rotoli B, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-a in chronic myelogenous leukemia. Blood. 1997;89:957\u201364.","DOI":"10.1182\/blood.V89.3.957"},{"key":"3006_CR127","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.4049\/jimmunol.165.7.3571","volume":"165","author":"C-K Lee","year":"2000","unstructured":"Lee C-K, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000;165:3571\u20137.","journal-title":"J Immunol"},{"key":"3006_CR128","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","volume":"178","author":"JB Swann","year":"2007","unstructured":"Swann JB, Hayakawa Y, Zerafa N, Sheehan KCF, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007;178:7540\u20139.","journal-title":"J Immunol"},{"key":"3006_CR129","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/jha2.1053","volume":"5","author":"H Ureshino","year":"2024","unstructured":"Ureshino H, Kamachi K, Kidoguchi K, Kimura S. IFN-\u03b1 treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP. eJHaem. 2024;5:1278\u201382.","journal-title":"eJHaem"},{"key":"3006_CR130","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989\u20132003.","journal-title":"J Exp Med"},{"key":"3006_CR131","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood-2003-03-0981","volume":"103","author":"L Gabriele","year":"2004","unstructured":"Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, et al. IFN-\u03b1 promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 2004;103:980\u20137.","journal-title":"Blood"},{"key":"3006_CR132","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","volume":"114","author":"M Talpaz","year":"1991","unstructured":"Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532\u20138.","journal-title":"Ann Intern Med"},{"key":"3006_CR133","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-\u03b1: a study of complete cytogenetic responders. Blood. 2001;98:3074\u201381.","journal-title":"Blood"},{"key":"3006_CR134","first-page":"1353","volume":"9","author":"T Lion","year":"1995","unstructured":"Lion T, Gaiger A, Henn T, H\u00f6rth E, Haas OA, Geissler K, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia. 1995;9:1353\u201360.","journal-title":"Leukemia"},{"key":"3006_CR135","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1200\/JCO.1998.16.4.1526","volume":"16","author":"R Kurzrock","year":"1998","unstructured":"Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. JCO. 1998;16:1526\u201331.","journal-title":"JCO"},{"key":"3006_CR136","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","volume":"18","author":"LA Kujawski","year":"2007","unstructured":"Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459\u201371.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3006_CR137","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935\u201342."},{"key":"3006_CR138","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"3006_CR139","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3006_CR140","doi-asserted-by":"crossref","unstructured":"Talpaz M, O\u2019Brien S, Rose E, Gupta S, Shan J, Cortes J, et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2 B (Schering 54031) in Philadelphia chromosome\u2013positive chronic myelogenous leukemia. Blood. 2001;98:1708\u201313.","DOI":"10.1182\/blood.V98.6.1708"},{"key":"3006_CR141","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10428190601175393","volume":"48","author":"JH Lipton","year":"2007","unstructured":"Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, et al. Phase II, randomized, multicenter, comparative study of peginterferon\u2013\u03b1\u20132a (40 kD) (Pegasys\u00ae) versus interferon \u03b1-2a (Roferon\u00ae-A) in patients with treatment-na\u00efve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48:497\u2013505.","journal-title":"Leuk Lymphoma"},{"key":"3006_CR142","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon Alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511\u201321.","journal-title":"N Engl J Med"},{"key":"3006_CR143","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/leu.2016.121","volume":"30","author":"H Hjorth-Hansen","year":"2016","unstructured":"Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, H\u00f6glund M, Dreimane A, et al. Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30:1853\u201360.","journal-title":"Leukemia"},{"key":"3006_CR144","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.18486","volume":"200","author":"L Roy","year":"2023","unstructured":"Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Dasatinib plus <span style=\u201cfont-variant:small-caps;\u201d>Peg-Interferon<\/span> alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (<span style=\u201cfont-variant:small-caps;\u201d>DASA-PegIFN<\/span> study). Br J Haematol. 2023;200:175\u201386.","journal-title":"Br J Haematol"},{"key":"3006_CR145","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152585","volume":"132","author":"J Huuhtanen","year":"2022","unstructured":"Huuhtanen J, Ilander M, Yadav B, Dufva OMJ, L\u00e4hteenm\u00e4ki H, Kasanen T, et al. IFN-\u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Investig. 2022;132:e152585.","journal-title":"J Clin Investig"},{"key":"3006_CR146","doi-asserted-by":"crossref","unstructured":"Nicolini FE, \u00c9tienne G, Huguet F, Guerci-Bresler A, Charbonnier A, Escoffre-Barbe M, et al. Treatment-free remissions in newly diagnosed CP CML patients treated with the combination of nilotinib + pegylated interferon Alpha 2a versus nilotinib alone in the national phase III petals trial<\/i>2021 2021\/11\/05\/. J Clin Med. 2024;18:1\u201312.","DOI":"10.1182\/blood-2021-146412"},{"key":"3006_CR147","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Burchert A, Sau\u00dfele S, Baerlocher GM, Mayer J, Br\u00fcmmendorf TH, et al. S157: Nilotinib vs. nilotinib + peg-interferon \u03b1lpha induction and nilotinib or peg-interferon \u03b1lpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. Tiger Trial 2023. Hemasphere. 2023;7:132\u2013133.","DOI":"10.1097\/01.HS9.0000967540.46956.59"},{"key":"3006_CR148","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/leu.2015.45","volume":"29","author":"A Burchert","year":"2015","unstructured":"Burchert A, Saussele S, Eigendorff E, M\u00fcller MC, Sohlbach K, Inselmann S, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29:1331\u20135.","journal-title":"Leukemia"},{"key":"3006_CR149","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P, Erben P, Bostel T, Liebler S, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. JCO. 2010;28:1429\u201335.","journal-title":"JCO"},{"key":"3006_CR150","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41375-025-02859-1","volume":"40","author":"A Burchert","year":"2026","unstructured":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, et al. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX). Leukemia. 2026;40:410\u20137.","journal-title":"Leukemia"},{"key":"3006_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35611","volume":"131","author":"T Kondo","year":"2025","unstructured":"Kondo T, Matsuki E, Takaku T, Watanabe N, Yoshida C, Okada M, et al. Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Cancer. 2025;131:e35611.","journal-title":"Cancer"},{"key":"3006_CR152","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505\u20138.","journal-title":"Blood"},{"key":"3006_CR153","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","volume":"60","author":"M \u0160mahel","year":"2011","unstructured":"\u0160mahel M. Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother. 2011;60:1655\u201368.","journal-title":"Cancer Immunol Immunother"},{"key":"3006_CR154","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","volume":"90","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529\u201334.","journal-title":"Blood"},{"key":"3006_CR155","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","volume":"88","author":"J Molldrem","year":"1996","unstructured":"Molldrem J, Dermime S, Parker K, Jiang Y, Mavroudis D, Hensel N, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450\u20137.","journal-title":"Blood"},{"key":"3006_CR156","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.21915","volume":"86","author":"JM Gerber","year":"2011","unstructured":"Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol. 2011;86:31\u20137.","journal-title":"Am J Hematol"},{"key":"3006_CR157","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/sj.leu.2402988","volume":"17","author":"C Rosenfeld","year":"2003","unstructured":"Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17:1301\u201312.","journal-title":"Leukemia"},{"key":"3006_CR158","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/modpathol.3800588","volume":"19","author":"S-i Nakatsuka","year":"2006","unstructured":"Nakatsuka S-i, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804\u201314.","journal-title":"Mod Pathol"},{"key":"3006_CR159","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","volume":"87","author":"M Bocchia","year":"1996","unstructured":"Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang S, Sette A, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587\u201392.","journal-title":"Blood"},{"key":"3006_CR160","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","volume":"88","author":"G Bosch","year":"1996","unstructured":"Bosch G, Joosten A, Kessler J, Melief C, Leeksma O. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996;88:3522\u20137.","journal-title":"Blood"},{"key":"3006_CR161","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/eji.1830270834","volume":"27","author":"A Buzyn","year":"1997","unstructured":"Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol. 1997;27:2066\u201372.","journal-title":"Eur J Immunol"},{"key":"3006_CR162","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI488","volume":"101","author":"P Yotnda","year":"1998","unstructured":"Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Investig. 1998;101:2290\u20136.","journal-title":"J Clin Investig"},{"key":"3006_CR163","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2003-07-2424","volume":"103","author":"H Fujiwara","year":"2004","unstructured":"Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood. 2004;103:3076\u201383.","journal-title":"Blood"},{"key":"3006_CR164","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"A Burchert","year":"2003","unstructured":"Burchert A, W\u00f6lfl S, Schmidt M, Brendel C, Denecke B, Cai D, et al. Interferon-\u03b1, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259\u201364.","journal-title":"Blood"},{"key":"3006_CR165","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31:697\u2013704.","journal-title":"Leukemia"},{"key":"3006_CR166","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3324\/haematol.2010.031674","volume":"96","author":"K Rezvani","year":"2011","unstructured":"Rezvani K, Yong ASM, Mielke S, Jafarpour B, Savani BN, Le RQ, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011;96:432\u201340.","journal-title":"Haematologica"},{"key":"3006_CR167","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","volume":"95","author":"J Pinilla-Ibarz","year":"2000","unstructured":"Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781\u20137.","journal-title":"Blood"},{"key":"3006_CR168","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037\u201342.","journal-title":"Blood"},{"key":"3006_CR169","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287\u201395.","journal-title":"Leukemia"},{"key":"3006_CR170","doi-asserted-by":"crossref","unstructured":"Bocchia M, Defina M, Ippoliti M, Amabile M, Breccia M, Iuliano F, et al. BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial 2009. Blood. 2009;114:648.","DOI":"10.1182\/blood.V114.22.648.648"},{"key":"3006_CR171","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/vaccines13040419","volume":"13","author":"A Sicuranza","year":"2025","unstructured":"Sicuranza A, Breccia M, Iuliano F, Gugliotta G, Castagnetti F, Lunghi M, et al. Therapeutic vaccinations with p210 peptides in imatinib-treated chronic myeloid leukemia patients: 10 years follow-up of GIMEMA CML0206 and SI0207 studies. Vaccines. 2025;13:419.","journal-title":"Vaccines"},{"key":"3006_CR172","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood.V89.4.1133","volume":"89","author":"A Choudhury","year":"1997","unstructured":"Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133\u201342.","journal-title":"Blood"},{"key":"3006_CR173","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1038\/sj.bmt.1702354","volume":"25","author":"J Westermann","year":"2000","unstructured":"Westermann J, Kopp J, K\u00f6rner I, Richter G, Qin Z, Blankenstein T, et al. Bcr\/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transpl. 2000;25:S46\u2013S9.","journal-title":"Bone Marrow Transpl"},{"key":"3006_CR174","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/sj.leu.2402979","volume":"17","author":"GJ Ossenkoppele","year":"2003","unstructured":"Ossenkoppele GJ, Stam AGM, Westers TM, de Gruijl TD, Janssen JJWM, van de Loosdrecht AA, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia. 2003;17:1424\u20136.","journal-title":"Leukemia"},{"key":"3006_CR175","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/14653240600735743","volume":"8","author":"MR Litzow","year":"2006","unstructured":"Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006;8:290\u20138.","journal-title":"Cytotherapy"},{"key":"3006_CR176","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2141.2007.06547.x","volume":"137","author":"J Westermann","year":"2007","unstructured":"Westermann J, Kopp J, Van Lessen A, Hecker AC, Baskaynak G, Le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr\/abl+ chronic myeloid leukaemia. Br J Haematol. 2007;137:297\u2013306.","journal-title":"Br J Haematol"},{"key":"3006_CR177","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-15-2163","volume":"22","author":"WT Curry","year":"2016","unstructured":"Curry WT, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, et al. Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016;22:2885\u201396.","journal-title":"Clin Cancer Res"},{"key":"3006_CR178","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.95.22.13141","volume":"95","author":"R Soiffer","year":"1998","unstructured":"Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte\u2013macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 1998;95:13141\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3006_CR179","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/08830180600992498","volume":"25","author":"KM Hege","year":"2006","unstructured":"Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol. 2006;25:321\u201352.","journal-title":"Int Rev Immunol"},{"key":"3006_CR180","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3006_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106737","volume":"111","author":"JA Webster","year":"2021","unstructured":"Webster JA, Robinson TM, Blackford AL, Warlick E, Ferguson A, Borrello I, et al. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leuk Res. 2021;111:106737.","journal-title":"Leuk Res"},{"key":"3006_CR182","doi-asserted-by":"crossref","unstructured":"Hellqvist E, Holm F, Mason CN, Runza V, Weigand S, Sadarangani A, et al. CD44 Monoclonal antibody-enhanced clearance of chronic myeloid leukemia stem cells from the malignant niche. Blood. 2013;122:858.","DOI":"10.1182\/blood.V122.21.858.858"},{"key":"3006_CR183","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood.V122.21.858.858","volume":"122","author":"E Hellqvist","year":"2013","unstructured":"Hellqvist E, Holm F, Mason CN, Runza V, Weigand S, Sadarangani A, et al. CD44 monoclonal antibody-enhanced clearance of chronic myeloid leukemia stem cells from the malignant niche. Blood. 2013;122:858.","journal-title":"Blood"},{"key":"3006_CR184","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/cancers11091358","volume":"11","author":"U Testa","year":"2019","unstructured":"Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers. 2019;11:1358.","journal-title":"Cancers"},{"key":"3006_CR185","doi-asserted-by":"crossref","unstructured":"Nievergall E, Ramshaw HS, Yong ASM, Biondo M, Busfield SJ, Vairo G, et al. Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218\u201328.","DOI":"10.1182\/blood-2012-12-475194"},{"key":"3006_CR186","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high-risk chronic myeloid leukemia. PLOS One. 2013;8:e55818.","journal-title":"PLOS One"},{"key":"3006_CR187","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.","journal-title":"J Hematol Oncol"},{"key":"3006_CR188","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1080\/10428194.2021.1889536","volume":"62","author":"J Mart\u00ednez-L\u00f3pez","year":"2021","unstructured":"Mart\u00ednez-L\u00f3pez J, Mustjoki S, Porkka K, Klisovic RB, Wolf D, Busque L, et al. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Leuk Lymphoma. 2021;62:2040\u20133.","journal-title":"Leuk Lymphoma"},{"key":"3006_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"3006_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217688","volume":"621","author":"Y Liu","year":"2025","unstructured":"Liu Y, Tu Y, Yan Z, Xiao J, Zhou B, Liu T, et al. CAR T-Cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: a multicenter clinical analysis. Cancer Lett. 2025;621:217688.","journal-title":"Cancer Lett"},{"key":"3006_CR191","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","volume":"35","author":"S Adnan Awad","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35:1087\u201399.","journal-title":"Leukemia"},{"key":"3006_CR192","doi-asserted-by":"crossref","unstructured":"Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Emerging CAR T cell strategies for the treatment of AML. Cancers. 2022;14:1\u201326.","DOI":"10.3390\/cancers14051241"},{"key":"3006_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012981","volume":"13","author":"Q Cui","year":"2022","unstructured":"Cui Q, Liang P, Dai H, Cui W, Cai M, Ding Z, et al. Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase. Front Immunol. 2022;13:1012981.","journal-title":"Front Immunol"},{"key":"3006_CR194","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","volume":"79","author":"W Warda","year":"2019","unstructured":"Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor\u2013engineered T cells. Cancer Res. 2019;79:663\u201375.","journal-title":"Cancer Res"},{"key":"3006_CR195","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86.","journal-title":"Biomark Res"},{"key":"3006_CR196","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, R\u00fclicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123:3951\u201362.","journal-title":"Blood"},{"key":"3006_CR197","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.bbrc.2019.11.092","volume":"522","author":"S Zhou","year":"2020","unstructured":"Zhou S, Zhu X, Liu W, Cheng F, Zou P, You Y, et al. Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis. Biochem Biophys Res Commun. 2020;522:362\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"3006_CR198","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-025-00608-9","volume":"14","author":"J Guoyun","year":"2025","unstructured":"Guoyun J, Yuefeng Q, Zhenglan H, Zuowei Y, Hongyan Z, Ying Y, et al. CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells. Exp Hematol Oncol. 2025;14:14.","journal-title":"Exp Hematol Oncol"},{"key":"3006_CR199","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.18632\/oncotarget.12739","volume":"8","author":"D Ribatti","year":"2017","unstructured":"Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2017;8:7175\u201380.","journal-title":"Oncotarget"},{"key":"3006_CR200","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/bmt.2016.183","volume":"51","author":"RP Gale","year":"2016","unstructured":"Gale RP, Fuchs EJ. Is there really a specific graft-versus-leukaemia effect? Bone Marrow Transpl. 2016;51:1413\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"3006_CR201","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/leu.2011.224","volume":"26","author":"RP Gale","year":"2012","unstructured":"Gale RP, Opelz G. Commentary: Does immune suppression increase risk of developing acute myeloid leukemia? Leukemia. 2012;26:422\u20133.","journal-title":"Leukemia"},{"key":"3006_CR202","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/ijc.24439","volume":"125","author":"CM Vajdic","year":"2009","unstructured":"Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125:1747\u201354.","journal-title":"Int J Cancer"},{"key":"3006_CR203","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.leukres.2017.03.003","volume":"57","author":"RP Gale","year":"2017","unstructured":"Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leuk Res. 2017;57:109\u201311.","journal-title":"Leuk Res"},{"key":"3006_CR204","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","volume":"27","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803\u201312.","journal-title":"Leukemia"},{"key":"3006_CR205","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","volume":"35","author":"F Guilhot","year":"2021","unstructured":"Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, et al. Long-term outcome of imatinib 400\u2009mg compared to imatinib 600\u2009mg or imatinib 400\u2009mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia. 2021;35:2332\u201345.","journal-title":"Leukemia"},{"key":"3006_CR206","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood.V126.23.134.134","volume":"126","author":"L ROY","year":"2015","unstructured":"ROY L, Chomel J-C, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase ii trial, from the french intergroup of CML (Fi-LMC). Blood. 2015;126:134.","journal-title":"Blood"},{"key":"3006_CR207","doi-asserted-by":"crossref","unstructured":"Rezvani K, Yong ASM, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2017;111:236\u201342.","DOI":"10.1182\/blood-2007-08-108241"},{"key":"3006_CR208","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","volume":"16","author":"BD Smith","year":"2010","unstructured":"Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16:338\u201347.","journal-title":"Clin Cancer Res"},{"key":"3006_CR209","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/bjh.12978","volume":"166","author":"O Frolova","year":"2014","unstructured":"Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014;166:862\u201374.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03006-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:51Z","timestamp":1785521391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03006-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":209,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03006-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMS reports receiving research support from Novartis and Fulcrum Therapeutics. NPS has received honoraria from Novartis and reports receiving research support from Kumquat Biosciences. NH reports serving on a data monitoring committee for Incyte and reports receiving research support from Novartis and Pfizer. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}